<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of nonmalignant pleural effusions in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of nonmalignant pleural effusions in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of nonmalignant pleural effusions in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David J Feller-Kopman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fabien Maldonado, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pleural effusions are diagnosed in about 1.5 million individuals in the United States annually [<a href="#rid1">1</a>]. Among the causes, pleural infection, heart failure, and malignancy are the most common. Nonmalignant pleural effusions (NMPEs) have a wide variety of etiologies  (<a class="graphic graphic_table graphicRef73530" href="/d/graphic/73530.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef54055" href="/d/graphic/54055.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef122224" href="/d/graphic/122224.html" rel="external">table 3</a>) and cause significant morbidity and mortality [<a href="#rid2">2,3</a>]. There are no established guidelines to facilitate management of NMPEs and most management strategies rely on expert experience and data derived from patients with malignancy. Since the majority of patients with NMPEs have significant comorbidities, a multidisciplinary approach is often necessary for management.</p><p>Management of NMPE is discussed in this topic review. Treatment of malignant pleural effusions is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions"</a>.)</p><p class="headingAnchor" id="H2944328390"><span class="h1">ETIOLOGIES</span><span class="headingEndMark"> — </span>Because of the lack of definition and heterogeneity in etiology of NMPEs  (<a class="graphic graphic_table graphicRef73530" href="/d/graphic/73530.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef54055" href="/d/graphic/54055.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef122224" href="/d/graphic/122224.html" rel="external">table 3</a>), there are few large-scale epidemiological data describing the incidence or etiologies of NMPE. However, in our experience, NMPEs due to pleural infection (eg, parapneumonic effusion) and congestive heart failure are the most common. Less common etiologies include NMPEs due to chronic liver disease, kidney disease, asbestos, rheumatoid arthritis, lupus pleuritis, pancreatitis, pulmonary embolism, and cardiac surgery. Rare etiologies include drugs, hypothyroidism, chylothorax, and cholesterol pleural effusion. Occasionally, no etiology is initially apparent (ie, idiopathic NMPE). Noteworthy, is that patients can often have more than one etiology for their effusion (eg, malignancy and congestive heart failure) [<a href="#rid4">4</a>].</p><p>Data that support this distribution include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>One prospective study of 356 consecutive unselected patients with NMPE reported that 40 percent of NMPE were due to pleural infection and 24 percent were due to congestive heart failure. Most effusions were exudative in nature (73 percent) and unilateral (88 percent) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another prospective study of 308 patients who underwent thoracentesis, excluding patients with malignant pleural effusions, the vast majority of patients had congestive heart failure [<a href="#rid2">2</a>]. In patients with NMPEs, most unilateral effusions were exudates and most bilateral effusions were transudates.</p><p></p><p>The diagnostic evaluation of a pleural effusion is discussed separately. (See  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion"</a> and  <a class="medical medical_review" href="/d/html/6707.html" rel="external">"Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion"</a>.)</p><p class="headingAnchor" id="H3312041843"><span class="h1">INITIAL TREATMENT</span><span class="headingEndMark"> — </span>Initial treatment of patients with a symptomatic NMPE involves treating the primary disorder and draining the pleural effusion. NMPE is associated with a high mortality such that prompt management is critical [<a href="#rid2">2,3</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H1436250782"><span class="h2">Treat primary disorder</span><span class="headingEndMark"> — </span>In most cases the underlying disorder should be treated by starting or optimizing therapy. Treatment varies depending upon the etiology but may involve antibiotics for pneumonia, diuretics for heart failure, diuresis and transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax, ultrafiltration for fluid overload in patients with kidney failure, or nonsteroidal anti-inflammatories for lupus pleuritis. (See  <a class="medical medical_review" href="/d/html/119384.html" rel="external">"Management and prognosis of parapneumonic pleural effusion and empyema in adults"</a> and  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/d/html/1242.html" rel="external">"Hepatic hydrothorax", section on 'Management'</a> and  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Volume overload'</a> and  <a class="medical medical_review" href="/d/html/4681.html" rel="external">"Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H1931619412"><span class="h2">Drainage for symptomatic patients</span><span class="headingEndMark"> — </span>Most experts agree that patients with a symptomatic NMPE, should undergo a drainage procedure. In most cases, this involves thoracentesis under ultrasound guidance, though chest tube placement or placement of an indwelling pleural catheter (IPC) may be required. Choosing among these options is individualized and is often institution- or operator-dependent. Technical details and complications of both procedures are described separately. (See  <a class="medical medical_review" href="/d/html/6686.html" rel="external">"Ultrasound-guided thoracentesis"</a> and  <a class="medical medical_review" href="/d/html/17172.html" rel="external">"Large volume (therapeutic) thoracentesis: Procedure and complications"</a> and  <a class="medical medical_review" href="/d/html/7816.html" rel="external">"Thoracostomy tubes and catheters: Indications and tube selection in adults and children"</a>.)</p><p>Asymptomatic patients with NMPE do <strong>not</strong> typically require therapeutic pleural intervention. For example, following cardiac surgery many patients have small asymptomatic pleural effusions that do not typically require drainage. Such patients generally undergo observation clinically and radiologically (eg, every three to six weeks). The only indication for thoracentesis in asymptomatic patients with NMPE is for diagnostic purposes or if a complication such as hemorrhage or infection is suspected. A potential downside of not draining a moderate effusion in an asymptomatic patient is the creation of a visceral pleural peel and the development of nonexpandable lung (NEL). As there are minimally invasive ways to palliate patients with NEL (eg, placement of an IPC), it may not be necessary to drain asymptomatic effusions in patients with a known underlying diagnosis.</p><p>Assessing the contribution of the pleural effusion to symptoms is challenging. Typical symptoms include dyspnea, chest pain, or cough. In the absence of previous drainage, this decision requires considerable clinical judgement. In many cases, the degree of symptoms and estimated size of the effusion help facilitate this decision. For example, a small- to moderate-sized pleural effusion in a patient admitted with acute heart failure may not need drainage if they are diuresing adequately and symptoms are improving. In contrast, a patient with significant dyspnea and a large pleural effusion due to underlying pneumonia should have their effusion drained. (See  <a class="medical medical_review" href="/d/html/119384.html" rel="external">"Management and prognosis of parapneumonic pleural effusion and empyema in adults", section on 'Approach to drainage'</a>.)</p><p>When a drainage procedure is indicated, it should be performed as soon as is feasible, typically within 12 to 24 hours of presentation. This is especially true in patients in whom the pleural space may be infected (eg, complicated parapneumonic effusion, tuberculous pleuritis, or empyema) or patients with severe symptoms in whom drainage may avoid intubation and mechanical ventilation.</p><p>In general, the volume of fluid that can be removed safely is unknown, but 1 to 1.5 L is often quoted as the maximum amount that should be removed in one session to minimize the risk of complications, such as re-expansion pulmonary edema (RPE); however, some data suggest that RPE does not appear to be associated with the volume of fluid removed [<a href="#rid5">5</a>]. However, larger volumes may be removed when the benefits of symptom relief are felt to outweigh the risks. While pleural manometry may guide large-volume thoracentesis, it is not always readily available, and routine pleural pressure monitoring during large-volume thoracentesis does not appear to reduce symptoms of chest discomfort during drainage [<a href="#rid6">6</a>]. We reserve use of manometry for those in whom NEL is suspected. Large-volume thoracentesis and manometry are discussed separately. (See  <a class="medical medical_review" href="/d/html/17172.html" rel="external">"Large volume (therapeutic) thoracentesis: Procedure and complications"</a> and  <a class="medical medical_review" href="/d/html/16859.html" rel="external">"Measurement and interpretation of pleural pressure (manometry): Indications and technique"</a>.)</p><p>Noting the clinical response to drainage is important. It will identify the most likely etiology for patients in whom symptoms improve with drainage; those who demonstrate relief should respond to future drainage procedures should the dyspnea and pleural effusion recur or should additional drainage be needed. In contrast, those who do not respond may need to be investigated for an alternate explanation of their symptoms (eg, NEL, rapid reaccumulation of hepatic hydrothorax, severe underlying lung or cardiac disease, or pulmonary embolism). Drainage also distinguished patients with expandable lung from those with NEL, which will direct options for pleural palliation (ie, IPC placement versus attempts at pleurodesis).</p><p class="headingAnchor" id="H4220757196"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>In most cases, treatment of the underlying disorder and drainage of the pleural effusion may result in complete or partial resolution of both symptoms and the effusion. There are no data or guidelines supporting a suitable interval follow-up. However, it is reasonable to perform chest radiography or ultrasound at an interval timepoint when the underlying etiology is expected to improve. For example, this might be days for acute congestive heart failure, weeks for chronic congestive heart failure or pneumonia, or months for lupus pleuritis. Patients should be followed for complete resolution of both symptoms and the pleural effusion. If clinical or radiologic resolution is incomplete, then inadequate primary therapy or an alternate etiology should be sought. Patients who develop worsening symptoms during follow up should be reimaged to look for recurrence or complications (eg, hemorrhage or infection). (See <a class="local">'Management of persistent or first recurrent pleural effusion'</a> below.)</p><p class="headingAnchor" id="H3476237711"><span class="h1">MANAGEMENT OF PERSISTENT OR FIRST RECURRENT PLEURAL EFFUSION</span><span class="headingEndMark"> — </span>Most patients with NMPE are responsive to drainage and treatment of the primary disorder. However, a significant proportion persist or recur. In this population, prior to proceeding with definitive therapy to prevent recurrence (eg, pleurodesis or indwelling pleural catheter [IPC] placement), symptomatic pleural effusions should be redrained; the underlying cause of the NMPE reconfirmed; and nonexpandable lung [NEL], pleural infection, hepatic hydrothorax, and malignancy excluded. This approach is largely based upon expert experience since there are no data or guidelines to facilitate this decision. (See <a class="local">'Repeat thoracentesis'</a> below and <a class="local">'Clinical re-evaluation and additional testing'</a> below.)</p><p>Pleural effusions due to congestive heart failure (CHF) and hepatic hydrothorax are among the most common etiologies that result in recurrent or persistent pleural effusions. As an example, one retrospective study in patients with NMPE reported that among patients who needed an IPC for management of their effusion, almost half were due to CHF and 43 percent were due to hepatic hydrothorax [<a href="#rid7">7</a>]. Another retrospective study of 23 patients with NMPE who underwent IPC placement reported similar results (57 percent due to heart failure and 35 percent due to hepatic hydrothorax) [<a href="#rid8">8</a>]; an additional small proportion had recurrent NMPE due to trauma and idiopathic pleuritis (&lt;10 percent). Both of these studies may have underrepresented patients with NMPEs who are not suited to IPC (eg, patients with parapneumonic effusion).</p><p class="headingAnchor" id="H2632429666"><span class="h2">Repeat thoracentesis</span><span class="headingEndMark"> — </span>In most patients with persistent or recurrent symptomatic NMPE, repeat therapeutic thoracentesis under ultrasound guidance is generally the first-line option. Repeat thoracentesis is best suited to patients who experienced relief from drainage on presentation, patients with NMPEs that reaccumulate slowly (eg, once every four weeks or more), and patients with a grim prognosis (eg, expected survival less than two to four weeks). Together with optimization of medical therapy, this approach may be sufficient to avoid a definitive form of therapy (eg, pleurodesis or IPC placement) and provides the opportunity for additional pleural fluid analysis and/or pleural biopsy, if needed. In contrast, repeated drainage is generally avoided in asymptomatic patients and in patients who did not experience relief of symptoms with previous drainage. In the latter, investigations targeted at the reason for persistent symptoms is needed (eg, NEL, rapid reaccumulation from hepatic hydrothorax, severe underlying lung or cardiac disease, pulmonary embolism, or deconditioning).</p><p>In general, multiple thoracenteses are typically not recommended (more than two to three). The rationale for avoiding frequent thoracenteses is based upon the theoretical risk of introducing infection and inducing loculations as well as avoiding multiple unnecessary procedures when the effusion is clearly recurrent and requires definitive management. Recurrence of this degree should prompt reinvestigation of the etiology, particularly in patients with idiopathic NMPE [<a href="#rid9">9,10</a>]. (See <a class="local">'Clinical re-evaluation and additional testing'</a> below and <a class="local">'Pleurodesis'</a> below and <a class="local">'Indwelling pleural catheter'</a> below.)</p><p>Repeat thoracentesis can be performed at the bedside or in an office setting. Technical details regarding thoracentesis and details regarding use of manometry to guide the volume of fluid that can be removed safely and provide a diagnosis of NEL are provided separately. (See  <a class="medical medical_review" href="/d/html/6686.html" rel="external">"Ultrasound-guided thoracentesis"</a> and  <a class="medical medical_review" href="/d/html/17172.html" rel="external">"Large volume (therapeutic) thoracentesis: Procedure and complications"</a> and  <a class="medical medical_review" href="/d/html/16859.html" rel="external">"Measurement and interpretation of pleural pressure (manometry): Indications and technique"</a> and  <a class="medical medical_review" href="/d/html/6697.html" rel="external">"Diagnosis and management of pleural causes of nonexpandable lung"</a>.)</p><p class="headingAnchor" id="H3524886969"><span class="h2">Clinical re-evaluation and additional testing</span><span class="headingEndMark"> — </span>Recurrence of an NMPE despite primary therapy implies that the initial diagnosis was incorrect and another etiology is present or that the initial diagnosis is correct but the underlying therapy is inadequate (eg, poor compliance, resistance to therapy, failure of therapy). Exploring all options is appropriate at this juncture.</p><p>In most patients, the etiology of recurrence is clear and usually due to CHF. However, other important diagnoses to exclude are NEL, active pleural infection (eg, complicated parapneumonic effusion), pleural malignancy, and hepatic hydrothorax. Uncommon and rare etiologies of NMPE should also be kept in mind (eg, chylothorax, cholesterol effusion, effusions due to medications  (<a class="graphic graphic_table graphicRef122224" href="/d/graphic/122224.html" rel="external">table 3</a>)), testing for which is largely determined by clinical suspicion. (See <a class="local">'Exclude nonexpandable lung'</a> below and <a class="local">'Exclude active pleural infection'</a> below and <a class="local">'Exclude malignancy'</a> below and <a class="local">'Exclude other alternate diagnoses'</a> below.)</p><p>In patients with recurrent NMPE, we suggest the following clinical evaluation:</p><p class="bulletIndent1"><span class="glyph">●</span>Another in-depth history should be taken looking for symptoms suggestive of an occult cancer, history of asbestos exposure, past or current drug history, possible pneumonia or chest trauma in the recent past, and risk factors for or symptoms of chronic liver disease, heart failure, and connective tissue disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be re-examined for lymphadenopathy, abdominal masses, spider nevi or other signs of occult liver disease, yellow nails, elevated jugular venous pressure, fine inspiratory crackles, lower extremity edema, or the presence of a ventriculoperitoneal or ventriculopleural shunt.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All previous existing data should be reviewed including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pleural fluid analyses – Clinicians should re-examine Light's criteria for transudates and exudates from data derived from previous analyses. Whether nonroutine tests such as cytology, pH, cholesterol, triglyceride, amylase, or rheumatoid factor were performed should also be determined. When indicated, repeat diagnostic thoracentesis should be performed to confirm the transudative or exudative nature of the fluid and to look for unusual etiologies (eg, chylothorax, cholesterol pleural effusion). A pleural fluid albumin gradient &gt;1.2 g/dL can also help identify patients whose clinical picture is suggestive of CHF but whose pleural fluid analysis is an exudate by Light's criteria whereas the pleural fluid-serum albumin ratio &lt;0.6 can identify those with hepatic hydrothorax [<a href="#rid11">11</a>]. Details regarding Light's criteria and initial testing are discussed separately. (See  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chest computed tomography (CT) – Chest CT can reveal potential alternate explanations for a recurrent pleural effusion and if not already done, should be performed irrespective of whether the effusion has been drained or not [<a href="#rid12">12</a>]. Contrast is typically necessary for identifying pleural-based abnormalities (ie, "pleural-phased" contrast) and may also be needed to evaluate hilar or mediastinal disease associated with the effusion [<a href="#rid13">13,14</a>]. Abnormalities that may be diagnostically useful include a lung or pleural abnormality (to suggest primary or metastatic cancer or NEL), bronchiectasis (to support yellow nail syndrome), consolidation (to suggest parapneumonic effusion), cystic lung disease (to suggest chylous effusion from lymphangioleiomyomatosis), interstitial lung disease or nodules (to suggest underlying connective tissue disorder), subphrenic masses or ascites (to suggest an abdominal source or hepatic hydrothorax), bilateral hilar lymphadenopathy (to suggest sarcoidosis), enlarged pulmonary arteries (to suggest pulmonary hypertension), a misplaced catheter, or venous obstruction. (See  <a class="medical medical_review" href="/d/html/6688.html" rel="external">"Imaging of pleural effusions in adults"</a> and  <a class="medical medical_review" href="/d/html/4399.html" rel="external">"Imaging of pleural plaques, thickening, and tumors"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transthoracic echocardiography – If not already done, performing an echocardiogram in patients with recurrent NMPE of unclear etiology is appropriate. Echocardiography may reveal evidence of systolic or diastolic heart failure or valvular heart disease to explain a NMPE. Left-sided cardiac function or valvular disease that is disproportionate to the size of the effusion(s) may suggest the presence of pulmonary hypertension or another etiology. A "snowstorm" appearance of the left ventricle myocardium can be suggestive of amyloidosis. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Echocardiography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New data should be obtained when indicated. This includes routine laboratory tests, kidney and liver function tests, pleural manometry (if available), and repeat pleural fluid analysis and/or thoracoscopic biopsy. In most cases, such testing excludes the important diagnoses discussed in the sections below. Further testing depends upon the clinical suspicion for specific etiologies. (See  <a class="medical medical_review" href="/d/html/6707.html" rel="external">"Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion"</a>.)</p><p></p><p class="headingAnchor" id="H2722931665"><span class="h3">Reevaluate for congestive heart failure</span><span class="headingEndMark"> — </span>Since most cases of recurrent NMPE are due to CHF, reconfirming that diagnosis using existing and/or new testing should be performed. This initially involves obtaining an electrocardiograph (EKG), N-terminal pro-brain natriuretic peptide (NT-BNP) level, and a transthoracic echocardiogram (TTE). However, if the diagnosis of CHF is unclear (eg, when cardiac function is disproportionate to the size of the effusion), additional testing such as transesophageal echocardiography, exercise testing, and pulmonary artery catheterization may be needed to determine if serious valvular heart disease or pulmonary hypertension is present. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p class="headingAnchor" id="H1005402590"><span class="h3">Exclude active pleural infection</span><span class="headingEndMark"> — </span>A parapneumonic effusion is a pleural effusion associated with an underlying pneumonia. Pleural infection can also occur without underlying pneumonia, such as in the case of pleural tuberculosis or trauma  (<a class="graphic graphic_table graphicRef121162" href="/d/graphic/121162.html" rel="external">table 4</a>). In addition to Gram stain and culture of the pleural fluid, diagnostic yield can be significantly increased when the pleural fluid is inoculated into blood-culture bottles [<a href="#rid15">15</a>] or when pleural tissue is sent for culture [<a href="#rid16">16</a>]. In patients with recurrent NMPE, actively excluding infection is important because the mainstay of therapy is antibiotics and drainage rather than closure of the pleural space (ie, pleurodesis), which is contraindicated in this population. Diagnosis and management of parapneumonic pleural effusion are discussed separately. (See  <a class="medical medical_review" href="/d/html/119384.html" rel="external">"Management and prognosis of parapneumonic pleural effusion and empyema in adults"</a>.)</p><p>In some cases when active infection has resolved, the patients may present with the signs and symptoms of NEL. (See <a class="local">'Exclude nonexpandable lung'</a> below and  <a class="medical medical_review" href="/d/html/6697.html" rel="external">"Diagnosis and management of pleural causes of nonexpandable lung"</a> and  <a class="medical medical_review" href="/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults", section on 'Stage 3 (chronic organization)'</a>.)</p><p class="headingAnchor" id="H4098414345"><span class="h3">Exclude nonexpandable lung</span><span class="headingEndMark"> — </span>NEL refers to the inability of the lung to fully re-expand after thoracentesis. NEL has historically been separated into trapped lung and lung entrapment. Trapped lung can be due to the development of a fibrous pleural peel that encases the visceral pleura and prevents the lung from expanding fully while lung entrapment is due to an inflammatory process.</p><p>NEL occurs most commonly following treatment of an underlying inflammatory or infectious condition of the pleura. It may be suggested when a therapeutic thoracentesis does not improve dyspnea and when fluid is replaced by air after thoracentesis on chest imaging ("pneumothorax ex vacuo"). In most cases, the diagnosis is suggested clinically and radiologically (eg, CT may show visceral pleural thickening, septations, loculations, or scar tissue) and it can be confirmed with pleural manometry, if available.</p><p>Importantly, in patients with recurrent NMPE due to NEL, therapeutic thoracentesis is not beneficial; dyspnea is not typically relieved following thoracentesis and the pleural effusion will rapidly reaccumulate despite thoracentesis [<a href="#rid17">17</a>]. In addition, pleurodesis is not typically feasible in patients with NEL since adequate apposition of the visceral and parietal pleura cannot be achieved. Thus, clinicians should <strong>not</strong> proceed with pleurodesis for patients with recurrent NMPE unless NEL has been reasonably excluded or treated (eg, with decortication). In the patient with NEL who does have symptomatic improvement following initial thoracentesis, IPC placement may be a good option for palliation. Further details regarding diagnosis and management of NEL are provided separately. (See  <a class="medical medical_review" href="/d/html/6697.html" rel="external">"Diagnosis and management of pleural causes of nonexpandable lung"</a>.)</p><p class="headingAnchor" id="H2306577964"><span class="h3">Exclude malignancy</span><span class="headingEndMark"> — </span>In patients with recurrent NMPE, it is crucial to obtain adequate pleural biopsies to rule out malignancy before proceeding with pleurodesis. Although the yield is likely to be higher in patients with exudative pleural effusions, malignancy can be seen in approximately 5 percent of recurrent transudative effusions [<a href="#rid18">18-20</a>].</p><p>Thoracoscopic inspection of the pleural space followed by pleural biopsy is considered the gold standard for the diagnosis of pleural malignancy (multiple biopsies are usually performed in one setting). The optimal target site may be identified on previous chest CT/positron emission tomography (PET) imaging or pleural inspection. Cytology is not as sensitive or specific compared with thoracoscopic biopsy; sensitivity of pleural fluid cytology on initial thoracentesis is approximately 60 percent, which increases to approximately 90 percent after the third thoracentesis (likely due to progression of disease). In addition, yields differ depending upon the type of malignancy that affects the pleural membranes. As such, negative pleural fluid cytology does not rule out malignancy. Additionally, malignant pleural mesothelioma can be difficult to diagnose from pleural fluid cytology and often requires tissue biopsy. The approach to suspected pleural malignancy is provided separately. (See  <a class="medical medical_review" href="/d/html/88822.html" rel="external">"Selection of modality for diagnosis and staging of patients with suspected non-small cell lung cancer", section on 'Pleural (T2, T3, M1a)'</a> and  <a class="medical medical_review" href="/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging", section on 'Diagnosis and histology'</a>.)</p><p>The rationale for excluding malignancy at this point in patients with recurrent NMPE is that, if found, delay in diagnosis, staging, and initiation of therapy is avoided. In addition, attempting a pleural biopsy after pleurodesis in patients in whom malignant involvement of the pleural space is undiagnosed is fraught with difficulty (due to adhesions and hemorrhage). Management of malignant pleural effusion is provided separately. (See  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions"</a> and  <a class="medical medical_review" href="/d/html/6688.html" rel="external">"Imaging of pleural effusions in adults"</a> and  <a class="medical medical_review" href="/d/html/4399.html" rel="external">"Imaging of pleural plaques, thickening, and tumors"</a>.)</p><p class="headingAnchor" id="H2017340720"><span class="h3">Exclude hepatic hydrothorax</span><span class="headingEndMark"> — </span>In patients with recurrent NMPE, hepatic hydrothorax is one of the more common etiologies. Clinical evaluation and liver function tests may help exclude this as a possibility. Right upper quadrant ultrasound and biopsy may be needed for those without a known diagnosis of cirrhosis. (See  <a class="medical medical_review" href="/d/html/1242.html" rel="external">"Hepatic hydrothorax"</a> and  <a class="medical medical_review" href="/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3740737642"><span class="h3">Exclude other alternate diagnoses</span><span class="headingEndMark"> — </span>Depending on the clinical suspicion, most other diagnoses may require further imaging (eg, chest magnetic resonance imaging, PET, ultrasonography), hemodynamic testing (pulmonary arterial catheter, exercise testing), laboratory testing (eg, thyroid function tests, 24 hour urine for protein), serologic testing (for connective tissue disorders), or repeat pleural fluid analysis (eg, for triglycerides, cholesterol, chylomicrons, amylase level, rheumatoid factor, fungal, mycobacterial, or parasitic culture)  (<a class="graphic graphic_table graphicRef73530" href="/d/graphic/73530.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef54055" href="/d/graphic/54055.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef122224" href="/d/graphic/122224.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef50027" href="/d/graphic/50027.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef82213" href="/d/graphic/82213.html" rel="external">table 6</a>). Obtaining special testing depends upon the suspicion for the underlying disorder. Investigating pleural effusion of unclear etiology and treating special populations with NMPE are discussed separately. (See  <a class="medical medical_review" href="/d/html/6688.html" rel="external">"Imaging of pleural effusions in adults"</a> and  <a class="medical medical_review" href="/d/html/6707.html" rel="external">"Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion"</a> and <a class="local">'Special populations'</a> below.)</p><p class="headingAnchor" id="H457371040"><span class="h2">Maximize primary therapy</span><span class="headingEndMark"> — </span>Once the primary diagnosis(es) has been established, attempts should be made to ensure compliance and optimization of therapy for the underlying disease. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with extensive volume overload from long standing heart failure with chronic kidney function impairment may benefit from maximizing diuretic medications. In some cases, ultrafiltration or dialysis may be useful. In rare cases, evaluation for implantable devices or cardiac transplantation may also be indicated. (See  <a class="medical medical_review" href="/d/html/3495.html" rel="external">"Management of refractory heart failure with reduced ejection fraction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with advanced liver disease and hepatic hydrothorax may need optimization of their diuretic therapy, and consideration should also be given to transjugular intrahepatic portosystemic shunt (TIPS) and liver transplantation. (See  <a class="medical medical_review" href="/d/html/1242.html" rel="external">"Hepatic hydrothorax"</a>.)</p><p></p><p>Resolution of pleural effusions in some cases may take weeks or months (eg, tuberculous effusions, hypothyroidism, chylous effusion from lymphangioleiomyomatosis, parapneumonic effusions, cholesterol effusions, effusions from cardiac surgery). In such cases, examining imaging for signs of continued resolution may facilitate the decision of whether to proceed with increasing medical therapy or pleural intervention.</p><p>If it is assured that medical therapy has been optimized and the NMPE persists or recurs, definitive therapy to prevent recurrence is needed. (See <a class="local">'Refractory effusions'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">REFRACTORY EFFUSIONS</span><span class="headingEndMark"> — </span>Patients with symptomatic NMPEs that recur despite repeated thoracentesis (eg, &gt;2 to 3) and optimal medical therapy should undergo indwelling pleural catheter (IPC) placement and/or pleurodesis. While in the past pleurodesis was the preferred option, the emergence of IPCs have changed practice such that either of these options are now equally appropriate. For patients with a grim prognosis (eg, less than two to four weeks) or those who decline pleurodesis and IPC, repeat therapeutic thoracentesis is an option. Pleuroperitoneal or pleurovenous shunts or surgical pleurectomy are last resort options that are rarely used or needed.</p><p class="headingAnchor" id="H185640385"><span class="h2">Choosing among the options</span><span class="headingEndMark"> — </span>There are no guidelines and few data to guide the clinician when choosing among these options, and as such, we recommend that therapeutic options be discussed in a multidisciplinary fashion (ie, with pulmonary, thoracic and transplant surgery, and hepatology). The principles that underlie this choice are generally similar to those in patients with recurrent malignant pleural effusion. However, specific to patients with NMPE, when the risk of pleural space infection is considered high (eg, hepatic hydrothorax), then pleurodesis might be preferred, unless pleural fluid output is too high (eg, &gt;300 mL per day) [<a href="#rid21">21,22</a>]. Further details regarding this choice are provided separately. (See  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions", section on 'Choosing among the options'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Pleurodesis</span><span class="headingEndMark"> — </span>Pleurodesis refers to obliteration of the pleural space by the induction of pleural inflammation and fibrosis using a chemical sclerosant (ie, chemical pleurodesis usually using talc) or manual abrasion (ie, mechanical pleurodesis). Chemical pleurodesis may be performed through a chest tube (ie, talc slurry) at the bedside, or thoracoscopically (ie, talc poudrage). In contrast, mechanical pleurodesis is only performed thoracoscopically.</p><p class="headingAnchor" id="H134614419"><span class="h3">Patient selection</span><span class="headingEndMark"> — </span>Pleurodesis is best suited to patients with expandable lung whose pleural fluid reaccumulates over the course of days to weeks rather than months; repeat therapeutic thoracentesis is unlikely to be adequate in this group. However, pleurodesis is also an option for patients with slowly accumulating pleural effusions who prefer to avoid the inconvenience of repeat thoracentesis or an IPC. Patients with a grim prognosis are not suitable for pleurodesis. Pleurodesis can make future thoracic surgery challenging, which should be taken into consideration when making the decision to proceed with this procedure.</p><p class="headingAnchor" id="H1781994555"><span class="h3">Pleurodesis type</span><span class="headingEndMark"> — </span>There is significant variation in practice regarding the type of pleurodesis (chemical versus mechanical; slurry versus poudrage), chest tube size (large- versus small-bore) and number, and sclerosing agent used (talc versus other). Choosing among these options is often institution- and operator-dependent. Based upon available data derived from patients with malignant pleural effusions, we prefer chemical pleurodesis using talc slurry delivered at the bedside via a small-bore chest tube or talc poudrage. Technical aspects and complications of chemical pleurodesis and data supporting chemical pleurodesis in patients with malignant pleural effusion are discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6695.html" rel="external">"Chemical pleurodesis for the prevention of recurrent pleural effusion"</a> and  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions", section on 'Chemical pleurodesis alone (bedside or thoracoscopic)'</a>.)</p><p class="headingAnchor" id="H170153985"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Supported by case series, several types of NMPEs have been successfully managed by chemical pleurodesis, including those due to chronic ambulatory peritoneal dialysis [<a href="#rid23">23-26</a>], yellow nail syndrome [<a href="#rid27">27-29</a>], chylothorax [<a href="#rid30">30-33</a>], nephrotic syndrome [<a href="#rid34">34</a>], lupus pleuritis [<a href="#rid32">32,35</a>], heart failure [<a href="#rid36">36-39</a>], and hepatic hydrothorax [<a href="#rid40">40,41</a>]. Based upon data from several case series, chemical pleurodesis appears to be effective at managing most patients with NMPEs [<a href="#rid23">23-25,27,28,30-32,34,42-46</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 68 patients with NMPE, <a class="drug drug_general" data-topicid="9496" href="/d/drug information/9496.html" rel="external">talc pleurodesis</a> via chest tube was reported to be successful in 77 percent of patients [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 24 patients with NMPE, chemical pleurodesis was successful in 80 percent of patients [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series of 16 patients with NMPE, <a class="drug drug_general" data-topicid="9496" href="/d/drug information/9496.html" rel="external">talc pleurodesis</a> was completely successful in 12 (75 percent) and partially successful in another 3 (19 percent) [<a href="#rid45">45</a>].</p><p></p><p>The success rate may be lower in patients with hepatic hydrothorax (47 percent) and the morbidity and mortality greater, although the latter may be due to the nature of the underlying disorder rather than the procedure [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/1242.html" rel="external">"Hepatic hydrothorax", section on 'Pleurodesis'</a>.)</p><p>Importantly, the pleural space needs to be dry for optimal results. Thus, as much fluid as is possible should be removed prior to the application of sclerosant, which may explain the higher failure rate in those with hepatic hydrothorax. In the latter, some experts advocate the use of multiple chest tubes and large-volume paracentesis in order to keep the pleural space dry during the time of pleurodesis.</p><p class="headingAnchor" id="H11"><span class="h2">Indwelling pleural catheter</span><span class="headingEndMark"> — </span>IPCs are tunneled catheters that provide a means by which fluid is intermittently drained from the pleural space without repeated thoracentesis [<a href="#rid48">48,49</a>]. They are typically left in place for several weeks or for as long as needed or tolerated (weeks to months) and can be left in place indefinitely. IPC placement has the advantage of inducing spontaneous pleurodesis in 40 percent of patients or more. Spontaneous pleurodesis typically occurs within the first six weeks of placement, however success rates are not as high and complications are slightly higher than when used in patients with malignant pleural effusion [<a href="#rid50">50,51</a>]. IPCs can be an outpatient or inpatient procedure. Technical details and complications of IPC placement are provided separately. (See  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions", section on 'Indwelling pleural catheter (IPC)'</a>.)</p><p class="headingAnchor" id="H2183158000"><span class="h3">Patient selection</span><span class="headingEndMark"> — </span>IPC is an excellent option for patients who decline, fail, or are not candidates for pleurodesis (eg, frail patients, patients with limited life expectancy [eg, up to six months]) [<a href="#rid8">8,52-54</a>]. However, the patient, a loved-one, or a home healthcare aid needs to be able to perform intermittent drainage (eg, every day or every other day). Selecting patients for IPC and complications of their use (eg, infection) are discussed separately. (See  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions", section on 'Choosing among the options'</a> and  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions", section on 'Indwelling pleural catheter (IPC)'</a>.)</p><p class="headingAnchor" id="H1270587780"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Compared with patients who have malignant pleural effusions, data in the NMPE population that support IPC use are limited to case series [<a href="#rid7">7,8,50-57</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of thirteen retrospective studies (total 325 patients, half of whom had congestive heart failure), the estimated average rate of spontaneous pleurodesis was 51 percent [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another randomized study found no difference in the mean dyspnea score when IPC was compared with repeat thoracentesis in patients with refractory NMPE [<a href="#rid58">58</a>]. While thoracentesis resulted in fewer complications, IPCs reduced the number of invasive pleural procedures required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single-center retrospective study of 54 patients with NMPE, IPC use resulted in adequate symptom relief in 93 percent of patients without need for additional intervention (other than the intermittent drainage itself) [<a href="#rid7">7</a>]. The median length of insertion was six weeks, and the median survival was 3.2 months. Pleurodesis was achieved in 46 percent of those who survived for longer than one month. Approximately one-quarter developed complications, mostly mechanical obstruction of the IPC, and less commonly, infection. Patients with hepatic hydrothorax had the highest rate of complications (37 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another retrospective study of 23 patients with NMPE who underwent IPC placement, spontaneous pleurodesis occurred after an average of 111 days [<a href="#rid8">8</a>]. Time to spontaneous pleurodesis was shorter in those with NMPE due to heart failure and longer in those with NMPE due to hepatic hydrothorax. This was longer than that experienced by patients with malignant pleural effusions (36 days).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one retrospective study of eight patients who had end-stage kidney disease, IPC use resulted in improved dyspnea by two weeks after insertion, and spontaneous pleurodesis occurred in over one-third [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several case series also report success of IPC use in patients with hepatic hydrothorax, the details of which are discussed separately [<a href="#rid21">21,40,51,60-65</a>]. (See  <a class="medical medical_review" href="/d/html/1242.html" rel="external">"Hepatic hydrothorax", section on 'Refractory hydrothorax'</a> and  <a class="medical medical_review" href="/d/html/86296.html" rel="external">"Palliative care for patients with end-stage liver disease"</a>.)</p><p></p><p class="headingAnchor" id="H2423286247"><span class="h2">Others</span><span class="headingEndMark"> — </span>For patients with NMPEs who remain symptomatic and wish to minimize 'catheter days' after IPC or who have recurrence of symptoms after pleurodesis, management options include combining IPC with pleurodesis or repeat pleurodesis attempts.</p><p>Success rates may be higher when IPCs are combined with pleurodesis. As an example, one study of 36 patients with refractory NMPE from congestive heart failure reported that successful pleurodesis was achieved in 80 percent of patients when an IPC was placed following talc poudrage pleurodesis [<a href="#rid56">56</a>]. In contrast, the success rate was only 25 percent in patients who only had an IPC alone. Another randomized study found no difference in the mean dyspnea score when repeat thoracentesis was compared with IPC [<a href="#rid58">58</a>].</p><p>Last resorts are pleuroperitoneal or pleurovenous shunts for internal drainage or surgical pleurectomy [<a href="#rid66">66-68</a>]. Shunts have two one-way valves that allow unidirectional flow away from the pleural space to the peritoneum or the subclavian vein. Pleurectomy involves resection of visceral and parietal pleura. Both procedures are surgically invasive therapies that are technically difficult to perform. They are rarely done and data that support their use in patients with NMPE are limited. Pleurovenous shunting (eg, Denver shunt) resulted in successful palliation in 12 patients with right-sided NMPE for the one-year observation period of the study [<a href="#rid66">66</a>]. Only one patient had a shunt occlusion after four weeks and another had an early but unrelated death.</p><p>A more detailed discussion of these techniques for patients with malignant pleural effusion is provided separately. (See  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions", section on 'Repeat or combination procedures'</a> and  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions", section on 'Shunt'</a> and  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions", section on 'Pleurectomy'</a>.)</p><p class="headingAnchor" id="H1869253556"><span class="h1">SPECIAL POPULATIONS</span><span class="headingEndMark"> — </span>Treatment of NMPEs that deserve consideration of specific treatment approaches, other than that outlined in this topic, is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Parapneumonic effusions and empyema (see  <a class="medical medical_review" href="/d/html/119384.html" rel="external">"Management and prognosis of parapneumonic pleural effusion and empyema in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chylothorax (see  <a class="medical medical_review" href="/d/html/16356.html" rel="external">"Management of chylothorax"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cholesterol pleural effusions (see  <a class="medical medical_review" href="/d/html/16317.html" rel="external">"Clinical presentation, diagnosis, and management of cholesterol pleural effusions"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic hydrothorax (see  <a class="medical medical_review" href="/d/html/1242.html" rel="external">"Hepatic hydrothorax"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonexpandable lung (see  <a class="medical medical_review" href="/d/html/6697.html" rel="external">"Diagnosis and management of pleural causes of nonexpandable lung"</a>)</p><p></p><p class="headingAnchor" id="H445962740"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Few data are published that report the prognosis in patients with NMPEs. The prognosis likely varies with the underlying reason for the effusion and the response to treatment, although data suggest that the one-year mortality ranges from 25 to 55 percent. For those with refractory bilateral transudative effusions mortality is as high as 68 percent at one year and likely reflects the severity of underlying cardiac or liver disease [<a href="#rid2">2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>One retrospective study of 356 patients with NMPE reported that patients with cardiac, kidney, and hepatic failure had one-year mortality rates of 50 percent, 46 percent, and 25 percent, respectively [<a href="#rid3">3</a>]. Indicators of a poor prognosis were bilateral effusions (hazard ratio [HR] 3.55, 95% CI 2.22-5.68) and transudative effusions (HR 2.78; 95% CI 1.81-4.28).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort of 308 patients with both malignant and nonmalignant etiologies for their pleural effusion, the 30-day and one-year mortality in those with NMPEs was 29 and 55 percent respectively [<a href="#rid2">2</a>]. Patients with bilateral pleural effusion had a higher risk of death at 30 days (17 versus 47 percent; HR 2.58, 95% CI 1.44-4.63) and at one year (36 versus 69 percent; HR 2.32, 95% CI 1.55-3.48) compared with patients who had a unilateral effusion.</p><p></p><p class="headingAnchor" id="H175664174"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/17200.html" rel="external">"Patient education: Pleural effusion (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiologies</strong> – Nonmalignant pleural effusions (NMPEs) have a wide variety of etiologies  (<a class="graphic graphic_table graphicRef73530" href="/d/graphic/73530.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef54055" href="/d/graphic/54055.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef122224" href="/d/graphic/122224.html" rel="external">table 3</a>) and are associated with significant morbidity and mortality [<a href="#rid2">2,3</a>]. NMPEs due to pleural infection (eg, parapneumonic effusions) and congestive heart failure (CHF) are the most common etiologies. Less common etiologies include chronic liver disease or kidney function impairment, asbestos, rheumatoid arthritis, lupus pleuritis, pancreatitis, pulmonary embolism, and cardiac surgery. Other etiologies are rare. (See <a class="local">'Etiologies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong> – Most management strategies rely on expert experience and data derived from patients with malignant pleural effusions. Many patients with NMPEs have comorbidities such that a multidisciplinary approach is often necessary for optimal management. As initial therapy for patients with symptomatic NMPE, we perform the following (see <a class="local">'Initial treatment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treat the underlying disorder and drain the effusion</strong> – In most patients, we start or optimize therapy for the underlying disorder and drain the pleural effusion. Drainage is typically performed using needle thoracentesis under ultrasound guidance. Patients who are asymptomatic do not typically need to be treated. (See <a class="local">'Drainage for symptomatic patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Follow-up</strong> – In most patients, this approach results in complete or partial resolution of the pleural effusion. All patients should be followed clinically and radiologically until symptoms and the effusion resolve. There are no data or guidelines supporting a suitable interval follow-up. However, it is reasonable to perform chest radiography or ultrasound at an interval timepoint when the underlying etiology is expected to improve (eg, days for acute heart failure, weeks for chronic heart failure). Recurrence of symptoms should prompt immediate reimaging.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent or recurrent NMPE</strong> – Our approach to persistent or recurrent NMPE is the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Repeat drainage and pleural fluid analysis</strong> – For symptomatic patients who have persistent or a first recurrence of NMPE, we suggest that the effusion be redrained rather than proceeding directly to a definitive therapy (eg, pleurodesis or indwelling pleural catheter [IPC]) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Repeat pleural fluid analysis should also be performed to reconfirm the suspected diagnosis or rule out more serious pathologies. (See <a class="local">'Management of persistent or first recurrent pleural effusion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reevaluation of the etiology</strong> – In addition, the underlying cause of the NMPE should be reconfirmed. Since this is typically CHF, the clinician should review or obtain an electrocardiograph (EKG), N-terminal pro-brain natriuretic peptide (NT-proBNP) level, and a transthoracic echocardiogram (TTE). However, when the diagnosis of CHF is unclear, additional testing, such as transesophageal echocardiography, exercise testing, and pulmonary artery catheterization, may be needed to determine whether serious valvular heart disease or pulmonary hypertension is present. (See <a class="local">'Clinical re-evaluation and additional testing'</a> above and <a class="local">'Reevaluate for congestive heart failure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Important conditions to exclude</strong> – Nonexpandable lung (NEL), pleural infection, hepatic hydrothorax, and malignancy should also be excluded. This involves review of existing data and obtaining new data such as routine laboratory tests, kidney and liver function tests, pleural manometry (if available), chest CT, and repeat pleural fluid analysis and/or thoracoscopic biopsy. (See <a class="local">'Clinical re-evaluation and additional testing'</a> above and <a class="local">'Exclude nonexpandable lung'</a> above and <a class="local">'Exclude active pleural infection'</a> above and <a class="local">'Exclude malignancy'</a> above and <a class="local">'Exclude hepatic hydrothorax'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional testing</strong> – Selecting additional tests depends upon the suspicion for other disorders other than those listed but may include further imaging (eg, chest magnetic resonance imaging, positron emission tomography, ultrasound), laboratory testing (eg, thyroid function tests, 24-hour urine for protein), serologic testing (for connective tissue disorders), or repeat pleural fluid analysis (eg, for triglycerides, cholesterol, chylomicrons, amylase level, rheumatoid factor, fungal, mycobacterial, or parasitic culture)  (<a class="graphic graphic_diagnosticimage graphicRef126504" href="/d/graphic/126504.html" rel="external">image 1</a> and <a class="graphic graphic_table graphicRef54055" href="/d/graphic/54055.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef73530" href="/d/graphic/73530.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef122224" href="/d/graphic/122224.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef50027" href="/d/graphic/50027.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef82213" href="/d/graphic/82213.html" rel="external">table 6</a>). (See <a class="local">'Clinical re-evaluation and additional testing'</a> above and <a class="local">'Exclude other alternate diagnoses'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Further maximize therapy for the underlying disorder</strong> – Once the primary diagnosis has been established, attempts should be made to ensure compliance and optimization of therapy for the underlying disease. If it is assured that medical therapy has been optimized and the NMPE persists or recurs, definitive therapy to prevent recurrence is needed. (See <a class="local">'Maximize primary therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory NMPE</strong> – In patients with symptomatic NMPEs that recur despite repeated thoracentesis (eg, &gt;2 to 3) and optimal medical therapy, we suggest either an IPC or pleurodesis rather than repeat thoracentesis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Repeat therapeutic thoracentesis may be suitable for those with a grim prognosis or those who decline pleurodesis and IPC. Data to support any of these options are limited to case series and data extrapolated from patients with malignant pleural effusion. (See <a class="local">'Refractory effusions'</a> above and  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions", section on 'Choosing among the options'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pleurodesis</strong> – Pleurodesis is best suited to patients with expandable lung whose pleural fluid reaccumulates over the course of days to weeks rather than months. It is also an option for patients with slowly accumulating pleural effusions who prefer to avoid the inconvenience of repeat thoracentesis or an IPC. When choosing a sclerosant, we suggest talc rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients with a grim prognosis are not suitable for pleurodesis (eg, &lt;2 weeks). (See <a class="local">'Pleurodesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IPC</strong> – IPC is best suited for patients who fail, decline, or are not candidates for pleurodesis (eg, frail patients, patients with limited life expectancy [eg, up to six months]). IPCs are not suitable for patients who do not have the ability to perform intermittent drainage or patients in whom long-term drainage is anticipated (eg, longer that six months). (See <a class="local">'Indwelling pleural catheter'</a> above and  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions", section on 'Indwelling pleural catheter (IPC)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combination therapy, surgery</strong> – For patients with NMPEs who continue to have high output via their IPC and patients who fail pleurodesis, management options include combining IPC with pleurodesis or repeat pleurodesis attempts. Pleuroperitoneal or pleurovenous shunts or surgical pleurectomy are last resort options that are rarely used or needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special populations</strong> – Treatment of NMPEs that deserve consideration of specific treatment approaches, other than those outlined in this topic, include parapneumonic effusions and empyema, chylothorax, cholesterol pleural effusion, tuberculous pleural effusions, NEL, and hepatic hydrothorax. (See <a class="local">'Special populations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The prognosis likely varies with the underlying cause of the effusion and the response to treatment, although data report one-year mortalities ranging from 25 to 55 percent. Bilateral effusion may be an indicator of poor prognosis. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1256705847"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Peter Doelken, MD, FCCP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Light RW. Pleural diseases, 6th Ed., Lippincott Williams &amp;Wilkins, Philadelphia 2013.</li><li><a class="nounderline abstract_t">DeBiasi EM, Pisani MA, Murphy TE, et al. Mortality among patients with pleural effusion undergoing thoracentesis. Eur Respir J 2015; 46:495.</a></li><li><a class="nounderline abstract_t">Walker SP, Morley AJ, Stadon L, et al. Nonmalignant Pleural Effusions: A Prospective Study of 356 Consecutive Unselected Patients. Chest 2017; 151:1099.</a></li><li><a class="nounderline abstract_t">Bintcliffe OJ, Hooper CE, Rider IJ, et al. Unilateral Pleural Effusions with More Than One Apparent Etiology. A Prospective Observational Study. Ann Am Thorac Soc 2016; 13:1050.</a></li><li><a class="nounderline abstract_t">Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg 2007; 84:1656.</a></li><li><a class="nounderline abstract_t">Lentz RJ, Lerner AD, Pannu JK, et al. Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial. Lancet Respir Med 2019; 7:447.</a></li><li><a class="nounderline abstract_t">Frost N, Ruwwe-Glösenkamp C, Raspe M, et al. Indwelling pleural catheters for non-malignant pleural effusions: report on a single centre's 10 years of experience. BMJ Open Respir Res 2020; 7.</a></li><li><a class="nounderline abstract_t">Chalhoub M, Harris K, Castellano M, et al. The use of the PleurX catheter in the management of non-malignant pleural effusions. Chron Respir Dis 2011; 8:185.</a></li><li><a class="nounderline abstract_t">Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii4.</a></li><li><a class="nounderline abstract_t">Rahman NM, Ali NJ, Brown G, et al. Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii54.</a></li><li><a class="nounderline abstract_t">Bielsa S, Porcel JM, Castellote J, et al. Solving the Light's criteria misclassification rate of cardiac and hepatic transudates. Respirology 2012; 17:721.</a></li><li><a class="nounderline abstract_t">Corcoran JP, Acton L, Ahmed A, et al. Diagnostic value of radiological imaging pre- and post-drainage of pleural effusions. Respirology 2016; 21:392.</a></li><li><a class="nounderline abstract_t">Hallifax RJ, Talwar A, Wrightson JM, et al. State-of-the-art: Radiological investigation of pleural disease. Respir Med 2017; 124:88.</a></li><li><a class="nounderline abstract_t">Raj V, Kirke R, Bankart MJ, Entwisle JJ. Multidetector CT imaging of pleura: comparison of two contrast infusion protocols. Br J Radiol 2011; 84:796.</a></li><li><a class="nounderline abstract_t">Menzies SM, Rahman NM, Wrightson JM, et al. Blood culture bottle culture of pleural fluid in pleural infection. Thorax 2011; 66:658.</a></li><li><a class="nounderline abstract_t">Psallidas I, Kanellakis NI, Bhatnagar R, et al. A Pilot Feasibility Study in Establishing the Role of Ultrasound-Guided Pleural Biopsies in Pleural Infection (The AUDIO Study). Chest 2018; 154:766.</a></li><li><a class="nounderline abstract_t">Huggins JT, Sahn SA, Heidecker J, et al. Characteristics of trapped lung: pleural fluid analysis, manometry, and air-contrast chest CT. Chest 2007; 131:206.</a></li><li><a class="nounderline abstract_t">Moltyaner Y, Miletin MS, Grossman RF. Transudative pleural effusions: false reassurance against malignancy. Chest 2000; 118:885.</a></li><li><a class="nounderline abstract_t">Fernandez C, Martín C, Aranda I, Romero S. Malignant transient pleural transudate: a sign of early lymphatic tumoral obstruction. Respiration 2000; 67:333.</a></li><li><a class="nounderline abstract_t">Assi Z, Caruso JL, Herndon J, Patz EF Jr. Cytologically proved malignant pleural effusions: distribution of transudates and exudates. Chest 1998; 113:1302.</a></li><li><a class="nounderline abstract_t">Kniese C, Diab K, Ghabril M, Bosslet G. Indwelling Pleural Catheters in Hepatic Hydrothorax: A Single-Center Series of Outcomes and Complications. Chest 2019; 155:307.</a></li><li><a class="nounderline abstract_t">Porcel JM. Management of refractory hepatic hydrothorax. Curr Opin Pulm Med 2014; 20:352.</a></li><li><a class="nounderline abstract_t">Benz RL, Schleifer CR. Hydrothorax in continuous ambulatory peritoneal dialysis: successful treatment with intrapleural tetracycline and a review of the literature. Am J Kidney Dis 1985; 5:136.</a></li><li><a class="nounderline abstract_t">Simmons LE, Mir AR. A review of management of pleuroperitoneal communication in five CAPD patients. Adv Perit Dial 1989; 5:81.</a></li><li><a class="nounderline abstract_t">Rodriguez-Perez JC, Palop L, Plaza C, et al. Diagnosis and treatment of massive hydrothorax in CAPD. Perit Dial Bull 1984; 4:S49.</a></li><li><a class="nounderline abstract_t">Szeto CC, Chow KM. Pathogenesis and management of hydrothorax complicating peritoneal dialysis. Curr Opin Pulm Med 2004; 10:315.</a></li><li><a class="nounderline abstract_t">Nordkild P, Kromann-Andersen H, Struve-Christensen E. Yellow nail syndrome--the triad of yellow nails, lymphedema and pleural effusions. A review of the literature and a case report. Acta Med Scand 1986; 219:221.</a></li><li><a class="nounderline abstract_t">Hiller E, Rosenow EC 3rd, Olsen AM. Pulmonary manifestations of the yellow nail syndrome. Chest 1972; 61:452.</a></li><li><a class="nounderline abstract_t">Maldonado F, Tazelaar HD, Wang CW, Ryu JH. Yellow nail syndrome: analysis of 41 consecutive patients. Chest 2008; 134:375.</a></li><li><a class="nounderline abstract_t">Adler RH, Levinsky L. Persistent chylothorax. Treatment by talc pleurodesis. J Thorac Cardiovasc Surg 1978; 76:859.</a></li><li><a class="nounderline abstract_t">Weissberg D. Talc pleurodesis : a controversial issue. Poumon Coeur 1981; 37:291.</a></li><li><a class="nounderline abstract_t">Vargas FS, Milanez JR, Filomeno LT, et al. Intrapleural talc for the prevention of recurrence in benign or undiagnosed pleural effusions. Chest 1994; 106:1771.</a></li><li><a class="nounderline abstract_t">Akin H, Olcmen A, Isgorucu O, et al. Approach to patients with chylothorax complicating pulmonary resection. Thorac Cardiovasc Surg 2012; 60:135.</a></li><li><a class="nounderline abstract_t">Jenkins PG, Shelp WD. Recurrent pleural transudate in the nephrotic syndrome. A new approach to treatment. JAMA 1974; 230:587.</a></li><li><a class="nounderline abstract_t">Breuer GS, Deeb M, Fisher D, Nesher G. Therapeutic options for refractory massive pleural effusion in systemic lupus erythematosus: a case study and review of the literature. Semin Arthritis Rheum 2005; 34:744.</a></li><li><a class="nounderline abstract_t">Spicer AJ, Fisher JA. Recurring pleural effusion in congestive heart failure treated by pleurodesis. J Ir Med Assoc 1969; 62:177.</a></li><li><a class="nounderline abstract_t">Davidoff D, Naparstek Y, Eliakim M. The use of pleurodesis for intractable pleural effusion due to congestive heart failure. Postgrad Med J 1983; 59:330.</a></li><li><a class="nounderline abstract_t">Audier M, Boutin C, Arnaud A, D'Journo J. [Case of cardiac effusion treated by pleuroscopic talc spray]. Mars Med 1967; 104:866.</a></li><li><a class="nounderline abstract_t">Freeman RK, Ascioti AJ, Dake M, Mahidhara RS. A propensity-matched comparison of pleurodesis or tunneled pleural catheter for heart failure patients with recurrent pleural effusion. Ann Thorac Surg 2014; 97:1872.</a></li><li><a class="nounderline abstract_t">Cerfolio RJ, Bryant AS. Efficacy of video-assisted thoracoscopic surgery with talc pleurodesis for porous diaphragm syndrome in patients with refractory hepatic hydrothorax. Ann Thorac Surg 2006; 82:457.</a></li><li><a class="nounderline abstract_t">Jung Y, Song SY, Na KJ, et al. Minimally invasive surgical strategy for refractory hepatic hydrothorax. Eur J Cardiothorac Surg 2020; 57:881.</a></li><li><a class="nounderline abstract_t">Posen, G, Sachs, H. Treatment of recurrent pleural effusion in dialysis patients by talc insufflation (abstract). Trans Am Soc Artif Intern Organs 1979; 8:75.</a></li><li><a class="nounderline abstract_t">Lieberman J, Agliozzo CM. Intrapleural nitrogen mustard for treating chylous effusion of pulmonary lymphangioleiomyomatosis. Cancer 1974; 33:1505.</a></li><li><a class="nounderline abstract_t">Sudduth CD, Sahn SA. Pleurodesis for nonmalignant pleural effusions. Recommendations. Chest 1992; 102:1855.</a></li><li><a class="nounderline abstract_t">Glazer M, Berkman N, Lafair JS, Kramer MR. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest 2000; 117:1404.</a></li><li><a class="nounderline abstract_t">Steger V, Mika U, Toomes H, et al. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. Ann Thorac Surg 2007; 83:1940.</a></li><li><a class="nounderline abstract_t">Lee WJ, Kim HJ, Park JH, et al. Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis. Korean J Hepatol 2011; 17:292.</a></li><li><a class="nounderline abstract_t">Gilbert CR, Wahidi MM, Light RW, et al. Management of Indwelling Tunneled Pleural Catheters: A Modified Delphi Consensus Statement. Chest 2020; 158:2221.</a></li><li><a class="nounderline abstract_t">Miller CRJ, Chrissian AA, Lee YCG, et al. Key Highlights From the American Association for Bronchology and Interventional Pulmonology Evidence-Informed Guidelines and Expert Panel Report for the Management of Indwelling Pleural Catheters. Chest 2021; 159:920.</a></li><li><a class="nounderline abstract_t">Patil M, Dhillon SS, Attwood K, et al. Management of Benign Pleural Effusions Using Indwelling Pleural Catheters: A Systematic Review and Meta-analysis. Chest 2017; 151:626.</a></li><li><a class="nounderline abstract_t">Shojaee S, Rahman N, Haas K, et al. Indwelling Tunneled Pleural Catheters for Refractory Hepatic Hydrothorax in Patients With Cirrhosis: A Multicenter Study. Chest 2019; 155:546.</a></li><li><a class="nounderline abstract_t">Bhatnagar R, Reid ED, Corcoran JP, et al. Indwelling pleural catheters for non-malignant effusions: a multicentre review of practice. Thorax 2014; 69:959.</a></li><li><a class="nounderline abstract_t">Krishnan M, Cheriyath P, Wert Y, Moritz TA. The Untapped Potential of Tunneled Pleural Catheters. Ann Thorac Surg 2015; 100:2055.</a></li><li><a class="nounderline abstract_t">DePew ZS, Iqbal S, Mullon JJ, et al. The role for tunneled indwelling pleural catheters in patients with persistent benign chylothorax. Am J Med Sci 2013; 346:349.</a></li><li><a class="nounderline abstract_t">Srour N, Potechin R, Amjadi K. Use of indwelling pleural catheters for cardiogenic pleural effusions. Chest 2013; 144:1603.</a></li><li><a class="nounderline abstract_t">Majid A, Kheir F, Fashjian M, et al. Tunneled Pleural Catheter Placement with and without Talc Poudrage for Treatment of Pleural Effusions Due to Congestive Heart Failure. Ann Am Thorac Soc 2016; 13:212.</a></li><li><a class="nounderline abstract_t">Ferraro DM, French SK, Bell DG. Bilateral Indwelling Pleural Catheters for Pleural Effusions Secondary to Nonmalignant Superior Vena Cava Obstruction. Ann Am Thorac Soc 2018; 15:258.</a></li><li><a class="nounderline abstract_t">Walker SP, Bintcliffe O, Keenan E, et al. Randomised trial of indwelling pleural catheters for refractory transudative pleural effusions. Eur Respir J 2022; 59.</a></li><li><a class="nounderline abstract_t">Potechin R, Amjadi K, Srour N. Indwelling pleural catheters for pleural   effusions associated with end-stage renal   disease: a case series. Ther Adv Respir Dis 2015; 9:22.</a></li><li><a class="nounderline abstract_t">Northup PG, Harmon RC, Pruett TL, et al. Mechanical pleurodesis aided by peritoneal drainage: procedure for hepatic hydrothorax. Ann Thorac Surg 2009; 87:245.</a></li><li><a class="nounderline abstract_t">Chen A, Massoni J, Jung D, Crippin J. Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax. A Pilot Study. Ann Am Thorac Soc 2016; 13:862.</a></li><li><a class="nounderline abstract_t">Temes RT, Davis MS, Follis FM, et al. Videothoracoscopic treatment of hepatic hydrothorax. Ann Thorac Surg 1997; 64:1468.</a></li><li><a class="nounderline abstract_t">Mouroux J, Perrin C, Venissac N, et al. Management of pleural effusion of cirrhotic origin. Chest 1996; 109:1093.</a></li><li><a class="nounderline abstract_t">Runyon BA, Greenblatt M, Ming RH. Hepatic hydrothorax is a relative contraindication to chest tube insertion. Am J Gastroenterol 1986; 81:566.</a></li><li><a class="nounderline abstract_t">Hou F, Qi X, Guo X. Effectiveness and Safety of Pleurodesis for Hepatic Hydrothorax: A Systematic Review and Meta-Analysis. Dig Dis Sci 2016; 61:3321.</a></li><li><a class="nounderline abstract_t">Artemiou O, Marta GM, Klepetko W, et al. Pleurovenous shunting in the treatment of nonmalignant pleural effusion. Ann Thorac Surg 2003; 76:231.</a></li><li><a class="nounderline abstract_t">Hadsaitong D, Suttithawil W. Pleurovenous shunt in treating refractory nonmalignant hepatic hydrothorax: a case report. Respir Med 2005; 99:1603.</a></li><li><a class="nounderline abstract_t">Park SZ, Shrager JB, Allen MS, Nagorney DM. Treatment of refractory, nonmalignant hydrothorax with a pleurovenous shunt. Ann Thorac Surg 1997; 63:1777.</a></li></ol></div><div id="topicVersionRevision">Topic 6694 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Light RW. Pleural diseases, 6th Ed., Lippincott Williams &amp;Wilkins, Philadelphia 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25837039" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mortality among patients with pleural effusion undergoing thoracentesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28025056" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nonmalignant Pleural Effusions: A Prospective Study of 356 Consecutive Unselected Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27064965" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Unilateral Pleural Effusions with More Than One Apparent Etiology. A Prospective Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954079" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Large-volume thoracentesis and the risk of reexpansion pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30772283" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31958272" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Indwelling pleural catheters for non-malignant pleural effusions: report on a single centre's 10 years of experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21636653" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The use of the PleurX catheter in the management of non-malignant pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20696692" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20696694" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22372660" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Solving the Light's criteria misclassification rate of cardiac and hepatic transudates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545413" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Diagnostic value of radiological imaging pre- and post-drainage of pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28233652" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : State-of-the-art: Radiological investigation of pleural disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21159803" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Multidetector CT imaging of pleura: comparison of two contrast infusion protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21459855" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Blood culture bottle culture of pleural fluid in pleural infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29524388" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A Pilot Feasibility Study in Establishing the Role of Ultrasound-Guided Pleural Biopsies in Pleural Infection (The AUDIO Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218577" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Characteristics of trapped lung: pleural fluid analysis, manometry, and air-contrast chest CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10988229" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Transudative pleural effusions: false reassurance against malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10867607" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Malignant transient pleural transudate: a sign of early lymphatic tumoral obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9596310" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cytologically proved malignant pleural effusions: distribution of transudates and exudates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29990479" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Indwelling Pleural Catheters in Hepatic Hydrothorax: A Single-Center Series of Outcomes and Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24811830" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Management of refractory hepatic hydrothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3970020" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hydrothorax in continuous ambulatory peritoneal dialysis: successful treatment with intrapleural tetracycline and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2577434" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A review of management of pleuroperitoneal communication in five CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Diagnosis and treatment of massive hydrothorax in CAPD</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220759" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pathogenesis and management of hydrothorax complicating peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3962735" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Yellow nail syndrome--the triad of yellow nails, lymphedema and pleural effusions. A review of the literature and a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5046843" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pulmonary manifestations of the yellow nail syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18403655" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Yellow nail syndrome: analysis of 41 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/713591" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Persistent chylothorax. Treatment by talc pleurodesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7312761" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Talc pleurodesis : a controversial issue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7988198" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intrapleural talc for the prevention of recurrence in benign or undiagnosed pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21557161" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Approach to patients with chylothorax complicating pulmonary resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4479274" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Recurrent pleural transudate in the nephrotic syndrome. A new approach to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846590" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Therapeutic options for refractory massive pleural effusion in systemic lupus erythematosus: a case study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5770863" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Recurring pleural effusion in congestive heart failure treated by pleurodesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6878108" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The use of pleurodesis for intractable pleural effusion due to congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5630379" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : [Case of cardiac effusion treated by pleuroscopic talc spray].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24726601" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A propensity-matched comparison of pleurodesis or tunneled pleural catheter for heart failure patients with recurrent pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16863743" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy of video-assisted thoracoscopic surgery with talc pleurodesis for porous diaphragm syndrome in patients with refractory hepatic hydrothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31958113" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Minimally invasive surgical strategy for refractory hepatic hydrothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment of recurrent pleural effusion in dialysis patients by talc insufflation (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4834148" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Intrapleural nitrogen mustard for treating chylous effusion of pulmonary lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1446502" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pleurodesis for nonmalignant pleural effusions. Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10807829" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17532375" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22310793" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32561437" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Management of Indwelling Tunneled Pleural Catheters: A Modified Delphi Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33152319" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Key Highlights From the American Association for Bronchology and Interventional Pulmonology Evidence-Informed Guidelines and Expert Panel Report for the Management of Indwelling Pleural Catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27845052" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Management of Benign Pleural Effusions Using Indwelling Pleural Catheters: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30171863" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Indwelling Tunneled Pleural Catheters for Refractory Hepatic Hydrothorax in Patients With Cirrhosis: A Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24343783" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Indwelling pleural catheters for non-malignant effusions: a multicentre review of practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26294344" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The Untapped Potential of Tunneled Pleural Catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23426083" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The role for tunneled indwelling pleural catheters in patients with persistent benign chylothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23807028" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Use of indwelling pleural catheters for cardiogenic pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598967" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Tunneled Pleural Catheter Placement with and without Talc Poudrage for Treatment of Pleural Effusions Due to Congestive Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29388816" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bilateral Indwelling Pleural Catheters for Pleural Effusions Secondary to Nonmalignant Superior Vena Cava Obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34413152" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Randomised trial of indwelling pleural catheters for refractory transudative pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25548369" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Indwelling pleural catheters for pleural   effusions associated with end-stage renal   disease: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19101306" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mechanical pleurodesis aided by peritoneal drainage: procedure for hepatic hydrothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27015392" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax. A Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9386726" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Videothoracoscopic treatment of hepatic hydrothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8635335" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Management of pleural effusion of cirrhotic origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3717119" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hepatic hydrothorax is a relative contraindication to chest tube insertion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27456504" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effectiveness and Safety of Pleurodesis for Hepatic Hydrothorax: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12842547" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pleurovenous shunting in the treatment of nonmalignant pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291082" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pleurovenous shunt in treating refractory nonmalignant hepatic hydrothorax: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9205188" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Treatment of refractory, nonmalignant hydrothorax with a pleurovenous shunt.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
